Cipla receives final approval for ANDA Isoproterenol Hydrochloride Injection
(14 Jun 2018)
Cipla announced on 13 June 2018 that it has received final approval for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, single-use sterile Ampoule from the United States Food and Drug Administration (US FDA).